

AD_____

Award Number: W81XWH-08-1-0268

TITLE: Gp140/CDCPI IN THE DEVELOPMENT OF PROSTATE CANCER
METASTASIS

PRINCIPAL INVESTIGATOR: Beatrice Knudsen, M.D., Ph.D.

CONTRACTING ORGANIZATION: Cedars-Sinai Medical Center
Los Angeles, CA 90048

REPORT DATE: May 2012

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) May 2012		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 1 May 2011- 30 April 2012	
4. TITLE AND SUBTITLE Gp140/CDCPI IN THE DEVELOPMENT OF PROSTATE CANCER METASTASIS				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-08-1-0268	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Beatrice Knudsen, M.D., Ph.D.				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Cedars-Sinai Medical Center Los Angeles, CA 90048				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The purpose of the research is to analyze the expression and function of gp140/CDCP1, a regulator of SRC kinase activity in prostate cancer. The scope of the project in year 3 is to determine expression in tissues from patients. The main results are from immunohistochemical analyses of gp140 in normal prostate epithelium, primary prostate cancer and metastatic prostate cancer. Gp140 RNA expression and protein membrane expression, but not total protein expression, are significantly decreased in primary cancers compared to normal epithelium. In metastatic disease, total gp140 protein expression decreases and is significantly lower in bone compared to soft tissue metastases. Overall, gp140 expression decreases during metastatic progression, supporting the concept that the loss of gp140 facilitates tumor metastasis.					
15. SUBJECT TERMS prostate cancer, gp140/CDCP1, immunohistochemistry, tumor metastasis					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Annual Report for
KNUDSEN Lab, Cedars Sinai Hospital
(May 1, 2011 to April 30, 2012)

TABLE OF CONTENTS

Introduction	p.2
Body	P.2-3
Key research accomplishments	p.2-3
Reportable Outcomes	p.3
Conclusion	p.3
References	p.3-4

INTRODUCTION:

SUBJECT, PURPOSE, SCOPE -

Subject: The central hypothesis of this project is that loss of Gp140 expression promotes invasion and metastases in prostate cancer cells. Gp140 was discovered in the Carter lab in 1996, but little was known about its function until 2004 when it was discovered to be a substrate of Src kinases and a binding protein of PKC δ [1] [2-4]. More recently, several studies elucidated additional functions of Gp140/CDCP1, such as expression in stem cells [5], anoikis [6, 7], migration [8] and regulation of subcellular Src activity [9-11]. Furthermore, based on recent studies, the activity of Gp140/CDCP1 may be cancer type and context dependent as CDCP1 was noted to suppress [12, 13] as well as enhance tumor progression and metastasis [14-16]. Finally, an antibody against gp140/CDCP1 inhibited metastases in a subcutaneous xenograft model of PC3 cells [17]. Together these data highlight the important role of Gp140/CDCP1 in prostate cancer and warrant specific studies in prostate cancer to determine CDCP1's role in this cancer type.

The purpose of the research is to analyze the role of gp140/CDCP1 in prostate cancer metastasis and to determine whether targeting gp140/CDCP1 could serve as a treatment against metastatic prostate cancer.

The scope of the research includes experiments in cultured cells, in cell line xenografts and in human tissues.

BODY:

RESEARCH ACCOMPLISHMENTS –

With the activation of the grant at Cedars Sinai in the fall of 2011, Dr. Knudsen started to organize and plan experiments outlined in Task 3 and Task 4 of the statement of work.

“Task 3 (months 3-9, Dr. Knudsen): To investigate whether Gp140 regulates Tyr-phosphorylation of the AR by SFKs.

- We will measure changes in nuclear localization and Tyr-phosphorylation of AR after inducing phosphorylation of Gp140.
- We will analyze changes in AR activity after Gp140 phosphorylation using a luciferase reporter construct

The milestone at the end of this task is to evaluate using quantitative data whether or not phosphorylation of Gp140 regulates Tyr-phosphorylation of the AR.

Task 4 (months 6 – 24, Dr. Knudsen): To determine whether the expression level of Gp140 and of a Gp140 biomarker panel predicts the development of prostate cancer metastasis.”

To accomplish task 3 of the grant, Dr. Knudsen recruited a senior project scientist to the lab. Dr. Nishit Mukhopadhyay has extensive expertise in signal transduction, kinases and AR. He will determine whether CDCP1 regulates the phosphorylation of the AR by Src kinases. To this point, he has received antibodies from Dr. Carter to “activate” CDCP1 in prostate cancer cells.

To complete task 4, we established conditions for the CDCP1 antibody in formalin fixed and paraffin embedded (FFPE) tissues. We have hired a histotechnician and are optimizing the antibody in the laboratory at Cedars Sinai. In addition, we are obtaining clinical follow-up on 330 prostate cancer cases in the biobank at Cedars Sinai and will use this cohort to determine the association of CDCP1 expression and prostate cancer progression. We also established a state-of-the-art digital image analysis core and will be able to obtain more accurate, reproducible and sensitive expression measurements. Altogether, we have enhanced our resources to complete the research proposed in task 4.

REPORTABLE OUTCOMES - none

CONCLUSIONS:

With considerable leverage from the institution, we have established the infrastructure to pursue the remaining research that we proposed in task 3 and task 4 of the award. As of November 1st 2012, we hired the personnel to continue to work on the role of CDCP1 in prostate cancer metastases and will complete the research in a timely manner and publish the results.

REFERENCES

1. Brown TA, Yang TM, Zaitsevskaja T, Xia Y, Dunn CA, Sigle RO, Knudsen B, Carter WG: **Adhesion or plasmin regulates tyrosine phosphorylation of a novel membrane glycoprotein p80/gp140/CUB domain-containing protein 1 in epithelia.** *J Biol Chem* 2004, **279**(15):14772-14783.
2. Bhatt AS, Erdjument-Bromage H, Tempst P, Craik CS, Moasser MM: **Adhesion signaling by a novel mitotic substrate of src kinases.** *Oncogene* 2005, **24**(34):5333-5343.
3. Benes CH, Wu N, Elia AE, Dharia T, Cantley LC, Soltoff SP: **The C2 domain of PKCdelta is a phosphotyrosine binding domain.** *Cell* 2005, **121**(2):271-280.
4. Buhning HJ, Kuci S, Conze T, Rathke G, Bartolovic K, Grunebach F, Scherl-Mostageer M, Brummendorf TH, Schweifer N, Lammers R: **CDCP1 identifies a broad spectrum of normal and malignant stem/progenitor cell subsets of hematopoietic and nonhematopoietic origin.** *Stem Cells* 2004, **22**(3):334-343.
5. Ikeda JI, Morii E, Kimura H, Tomita Y, Takakuwa T, Hasegawa JI, Kim YK, Miyoshi Y, Noguchi S, Nishida T *et al*: **Epigenetic regulation of the expression of the novel stem cell marker CDCP1 in cancer cells.** *J Pathol* 2006, **210**(1):75-84.
6. Uekita T, Jia L, Narisawa-Saito M, Yokota J, Kiyono T, Sakai R: **CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma.** *Mol Cell*

- Biol*2007, **27**(21):7649-7660.
7. Spasov DS, Baehner FL, Wong CH, McDonough S, Moasser MM: **The transmembrane srcsubstrate Trask is an epithelial protein that signals during anchorage deprivation.** *Am J Pathol* 2009, **174**(5):1756-1765.
 8. Benes CH, Poulogiannis G, Cantley LC, Soltoff SP: **The SRC-associated protein CUB Domain-Containing Protein-1 regulates adhesion and motility.** *Oncogene* 2012, **31**(5):653-663.
 9. Wortmann A, He Y, Christensen ME, Linn M, Lumley JW, Pollock PM, Waterhouse NJ, Hooper JD: **Cellular settings mediating Src Substrate switching between focal adhesion kinase tyrosine 861 and CUB-domain-containing protein 1 (CDCP1) tyrosine 734.** *J Biol Chem* 2011, **286**(49):42303-42315.
 10. Spasov DS, Wong CH, Moasser MM: **Trask phosphorylation defines the reverse mode of aphosphotyrosine signaling switch that underlies cell anchorage state.** *Cell Cycle* 2011, **10**(8):1225-1232.
 11. Spasov DS, Wong CH, Sergina N, Ahuja D, Fried M, Sheppard D, Moasser MM: **Phosphorylation of Trask by Src kinases inhibits integrin clustering and functions in exclusion with focal adhesion signaling.** *Mol Cell Biol* 2011, **31**(4):766-782.
 12. Spasov DS, Wong CH, Harris G, McDonough S, Phojanakong P, Wang D, Hann B, Bazarov AV, Yaswen P, Khanafshar E *et al*: **A tumor-suppressing function in the epithelial adhesion protein Trask.** *Oncogene* 2012, **31**(4):419-431.
 13. Fukuchi K, Steiniger SC, Deryugina E, Liu Y, Lowery CA, Gloeckner C, Zhou B, Kaufmann GF, Quigley JP, Janda KD: **Inhibition of tumor metastasis: functional immune modulation of the CUB domain containing protein 1.** *Mol Pharm* 2010, **7**(1):245-253.
 14. Ikeda J, Oda T, Inoue M, Uekita T, Sakai R, Okumura M, Aozasa K, Morii E: **Expression of CUB domain containing protein (CDCP1) is correlated with prognosis and survival of patients with adenocarcinoma of lung.** *Cancer Sci* 2009, **100**(3):429-433.
 15. Awakura Y, Nakamura E, Takahashi T, Kotani H, Mikami Y, Kadowaki T, Myoumoto A, Akiyama H, Ito N, Kamoto T *et al*: **Microarray-based identification of CUB-domaincontaining protein 1 as a potential prognostic marker in conventional renal cell carcinoma.** *J Cancer Res Clin Oncol* 2008, **134**(12):1363-1369.
 16. Uekita T, Tanaka M, Takigahira M, Miyazawa Y, Nakanishi Y, Kanai Y, Yanagihara K, Sakai R: **CUB-domain-containing protein 1 regulates peritoneal dissemination of gastric scirrhou carcinoma.** *Am J Pathol* 2008, **172**(6):1729-1739.
 17. Siva AC, Wild MA, Kirkland RE, Nolan MJ, Lin B, Maruyama T, Yantiri-Wernimont F, Frederickson S, Bowdish KS, Xin H: **Targeting CUB domain-containing protein 1 with a monoclonal antibody inhibits metastasis in a prostate cancer model.** *Cancer Res* 2008, **68**(10):3759-3766.